You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Journal logo
Sections
Ask the Ethicist
At the Bench
Best Advances
Disease Mechanisms
Diversity
For Your Patients
In the Pipeline
Off the Clock
Neurotech
Letters to the Editor
Policy and Practice
Professionalism
The Science Explained
Wellness
Topics
Behavioral Neurology/Dementia
Cerebrovascular Disease
Child Neurology
Epilepsy
Genetics
Headache/Facial Pain
Movement Disorders
Multiple Sclerosis
Neurocritical Care
Neuroinfectious Disease
Neuromuscular
Neuro-oncology
Neuro-ophthalmology/Neuro-otology
Sleep Neurology
Sports Neurology/Concussion
At the Meetings
Meetings We Cover
Most Recent Meeting
About
About Neurology Today
Editorial Board
Subscription Services
Reprints
Rights and Permissions
About the AAN
American Academy of Neurology
Account
Register
Help
American Academy of Neurology
Login
Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy.
Subscribe to eTOC
Home
>
Issue Outline
January 16, 2014
Volume 14, Issue 2
Browse Issues
For Your Patients
For Your Patients
Neurologists See Some Gains in CMS' 2014 Fee Schedule
For Your Patients
Why Neurointensivists Are Rethinking the Prehospital Hypothermia Protocol After Cardiac Arrest
For Your Patients
FDA to 23andMe: ‘Stop Marketing Genetic Tests’
For Your Patients
New AAN Guideline: The Evidence for Screening and Treating Psychiatric Disorders in MS
For Your Patients
FROM THE AMERICAN HEADACHE SOCIETY: ‘Choosing Wisely’: 5 Things Neurologists and Patients Should Question about Migraine
For Your Patients
What Does FDA's ‘Breakthrough’ Pathway Mean for Neurology?
For Your Patients
Meningitis B Outbreaks Prompt Different Emergency Responses
For Your Patients
Nearly One-Third of Large Clinical Trials Go Unpublished — in Neurology, Too
For Your Patients
NEWS FROM THE SOCIETY FOR NEUROSCIENCE ANNUAL MEETING: An Early Report: APOE Modifier for Alzheimer's Could Be Ready for Human Trials
For Your Patients
TUNE IN, JOIN IN THE DIALOGUE: How do metabolic syndrome and time spent in the ICU contribute to cognitive decline?
Issue Cover
Editor's Pick Podcast
Back to Top
